Chronic myeloid leukemia

Abstract

In attempting to apply evidence-based medicine in the treatment of chronic myeloid leukemia (CML), it must be acknowledged that a randomized study comparing imatinib mesylate therapy and allogeneic stem cell transplantation (SCT) has not been conducted. The question that will remain at the end of this chapter is whether such a study is feasible, or even ethical. The treatment of CML could represent a paradigm in oncology as well as a unique set of challenges. © 2006 Springer Science+Business Media, Inc.